Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion.

Abstract
Introduction: Mineralocorticoid receptor antagonists (MRAs) are effective in reducing left ventricle remodeling and sudden death after acute myocardial infarction (AMI). Objectives: MRAs in vitro display cardioprotective effects, independent of MR; however, it is unknown whether the rapid effects of MRAs are cardioprotective in vivo. This study evaluated the acute effects of spironolactone and eplerenone in the first minutes of AMI. Methods: Wistar Rats, submitted or not to bilateral adrenalectomy, were treated orally with spironolactone (20 mg/kg) or eplerenone (10 mg/kg), and submitted to the left coronary ligation, under anesthesia. Electrocardiogram (ECG) recordings were obtained to evaluate ST-T segment, QT, and QTc intervals. Arterial pressure was also measured before (baseline) and after coronary ligation. Results: Spironolactone or eplerenone given, one hour before coronary ligation, prevented ST- T segment elevation in adrenalectomized and non-adrenalectomized. QT interval analysis showed that MRAs prevented its prolongation after coronary ligation. QT and QTc intervals remained similar to baseline and were smaller than the values displayed by the non-treated group. Animals treated with spironolactone, regardless of adrenalectomy, showed a 3-fold reduced mortality rates compared to the control group. Conclusion: MRAs display acute cardioprotective effects in early phase of AMI, which are independent of aldosterone.
Description
Keywords
Acute myocardial infarction, Electrocardiogram, Infarto agudo do miocárdio, Eletrocardiograma
Citation
AMANCIO, G. de C. S. et al. Spironolactone and eplerenone are cardioprotective during early phase of ischemia in rats submitted to acute coronary occlusion. Research, Society and Development, v. 11, n. 3, 2022. Disponível em: <https://rsdjournal.org/index.php/rsd/article/view/26498>. Acesso em: 11 out. 2022.